Zydus Lifesciences Limited

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 09:03:24 2024-04-25 am EDT			5-day change	1st Jan Change
951.2 ^INR	+1.90%		+1.52%	+38.02%

Apr. 24	Zydus Lifesciences Gets 10 Observations from US FDA After Jarod, India Manufacturing Site Inspection	MT
Apr. 23	China Medical System's Anti-Anaemia NDA Accepted in China	MT

Cadila Healthcare : Zydus announces ‘first patient’ randomised in EVIDENCES-X TM Phase II(b) clinical trial of Saroglitazar Mg in NASH

October 22, 2021 at 09:14 am EDT

www.zyduscadila.com is using a security service for protection against online attacks. This process is automatic. You will be redirected once the validation is complete.

Reference ID	IP Address	Date and Time
8946b0739bb182bd1a59ff3123401467	18.188.216.125	10/22/2021 01:03 PM UTC

Attachments

Original document
Permalink

Disclaimer

Cadila Healthcare Limited published this content on 22 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 October 2021 13:13:01 UTC.

Latest news about Zydus Lifesciences Limited

Zydus Lifesciences Gets 10 Observations from US FDA After Jarod, India Manufacturing Site Inspection	Apr. 24	MT
China Medical System's Anti-Anaemia NDA Accepted in China	Apr. 23	MT
Zydus Lifesciences' Desidustat Tablets Get Nod from China Regulator	Apr. 23	MT
Zydus Lifesciences Limited Announces New Drug Application of Zydus' Innovative Drug Desidustat Tablets by China Medical System Holdings Limited Accepted in China	Apr. 23	CI
Zydus Lifesciences Limited Launches Mirabegron Extended-Release Tablets in the U.S	Apr. 22	CI
Zydus Arm Get UK Drug Regulator's Marketing Approval for Nulibry as MoCD Type A Treatment	Apr. 21	MT
Zydus Lifesciences Launches Generic Drug for Overactive Bladder in US	Apr. 21	MT
Zydus Receives Approval from WHO International Non-Proprietary Names for Usnoflast as Recommended Name for ZYIL1	Apr. 01	CI
Zydus Gets Four Observations from US FDA for Oncology Injectable Plant	Mar. 28	MT
Zydus Lifesciences Limited Receives Tentative Approval from USFDA for Letermovir Tablets, 240 Mg and 480 Mg	Mar. 23	CI
Zydus Lifesciences Gets US FDA's Final Nod for Finasteride and Tadalafil Capsules	Mar. 17	MT
Zydus Lifesciences Limited Receives Final Approval from USFDA and 180 Days CGT Exclusivity for Finasteride and Tadalafil Cap Capsules	Mar. 16	CI
Tranche Update on Zydus Lifesciences Limited's Equity Buyback Plan announced on February 9, 2024.	Mar. 15	CI
Zydus Lifesciences Gets US FDA Final Nod for Chlorpromazine Hydrochloride Injection; Shares Jump 3%	Mar. 14	MT
Zydus Receives Final Approval from the USFDA for Chlorpromazine Hydrochloride Injection USP, 25 mg/mL and 50 mg/2 mL (25 mg/mL), Single-Dose Vials	Mar. 14	CI
Zydus Receives Tentative Approval from the USFDA for Edaravone Injection, 30 mg/100 mL (0.3 mg/mL), Single-Dose Vial	Mar. 14	CI
Zydus Lifesciences Launches Generic Cancer Drug Ibyra in India	Mar. 13	MT
Zydus Lifesciences Limited Launches IBYRA, the Generic Version of Olaparib	Mar. 13	CI
Zydus Lifesciences Gets US FDA's EIR for Ahmedabad, India Unit's Inspection	Mar. 11	MT
Zydus Lifesciences Limited's Equity Buyback announced on February 9, 2024, has closed with 5,970,149 shares, representing 0.59% for INR 6,000 million.	Mar. 05	CI
Zydus Lifesciences Forms UAE-Based Arm	Feb. 22	MT
Zydus Lifesciences Limited Announces Incorporation of Wholly Owned Subsidiary Company	Feb. 22	CI
Zydus Lifesciences Gets US FDA Final Approval for Generic Chest Pain Drug	Feb. 16	MT
Zydus Lifesciences Limited Receives Final Approval from the United States Food and Drug Administration for Isosorbide Mononitrate Extended-Release, Tablets USP, 30 mg, 60 mg, and 120 mg	Feb. 16	CI
Jefferies Adjusts Zydus Lifesciences’ Price Target to INR750 From INR660, Keeps at Hold	Feb. 12	MT

Chart Zydus Lifesciences Limited

Duration

Period

More charts

Company Profile

Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.

Sector

Pharmaceuticals

Calendar

2024-05-23 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Zydus Lifesciences Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

951.2 INR

Average target price

844.6 INR

Spread / Average Target

-11.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
ZYDUS LIFESCIENCES LIMITED	+38.02%	11.27B
OTSUKA HOLDINGS CO., LTD.	+18.51%	22.25B
SANDOZ GROUP AG	+13.49%	14.39B
CIPLA LIMITED	+12.83%	13.55B
ONO PHARMACEUTICAL CO., LTD.	-10.61%	6.95B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+6.35%	5.01B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-5.36%	4.51B
RICHTER GEDEON VEGYÉSZETI GYÁR NYILVÁNOSAN MUKÖDO RT.	+2.40%	4.51B

Generic Pharmaceuticals

Zydus Lifesciences Limited

Equities

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Cadila Healthcare : Zydus announces ‘first patient’ randomised in EVIDENCES-X TM Phase II(b) clinical trial of Saroglitazar Mg in NASH

EPS Revisions